» Articles » PMID: 1569148

Basal- and Insulin-stimulated Substrate Metabolism in Patients with Active Acromegaly Before and After Adenomectomy

Overview
Specialty Endocrinology
Date 1992 May 1
PMID 1569148
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Active acromegaly is characterized by inappropriate tissue growth, increased mortality, and perturbations of intermediary metabolism. It is, in general, not well described to which extent these disturbances are normalized after treatment of the disease. To further assess basal and insulin stimulated fuel metabolism in acromegaly six patients with monotropic GH excess were each studied approximately 1 month prior to and 2 months after successful selective pituitary adenomectomy and compared to a control population of seven subjects. The studies consisted of a 3-h basal postabsorptive period and a 2-h hyperinsulinaemic (0.4 mU/kg/min) euglycemic clamp and the methods employed included isotopical measurement of glucose turnover, indirect calorimetry, and the forearm technique. When compared to the control subjects the patients with acromegaly were preoperatively and in the basal state characterized by: 1) increased circulating concentrations of GH, insulin, and C-peptide (P less than 0.05); 2) increased plasma glucose (5.9 +/- 0.2 vs. 5.2 +/- 0.2 mmol/L), blood lactate (710 +/- 90 vs. 580 +/- 70 mumol/L), glucose turnover (2.34 +/- 0.12 vs. 1.93 +/- 0.12 mg/kg/min), and plasma lipid intermediates and a decreased forearm glucose uptake (0.06 +/- 0.02 vs. 0.19 +/- 0.04 mmol/L) (P less than 0.05); and 3) a 20% increase in energy expenditure, a 50% elevation of lipid oxidation rates, and a 130% elevation of nonoxidative glucose turnover (P less than 0.05). During the clamp the patients with active acromegaly were substantially resistant to the actions of insulin on both glucose and lipid metabolism. Following pituitary surgery all of these metabolic abnormalities were abolished. We conclude that active acromegaly is characterized by profound disturbances of not only glucose but also lipid metabolism, which in theory may precipitate the increased mortality in this disease. By showing that these abnormalities and the concomitant overall insulin resistance can be completely reversed our results may also have important implications for other insulin-resistant states and for the potential therapeutic use of GH.

Citing Articles

Glucose metabolism outcomes after pituitary surgery in patients with acromegaly.

Pascual-Corrales E, Biagetti B, Marazuela M, Asensio-Wandosel D, Berrocal V, Irigaray Echarri A Pituitary. 2024; 27(5):497-506.

PMID: 38940859 DOI: 10.1007/s11102-024-01415-x.


Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management.

Esposito D, Boguszewski C, Colao A, Fleseriu M, Gatto F, Jorgensen J Nat Rev Endocrinol. 2024; 20(9):541-552.

PMID: 38844688 DOI: 10.1038/s41574-024-00993-x.


Glucose intolerance in acromegaly is driven by low insulin secretion; results from an intravenous glucose tolerance test.

Zaifu L, Niculescu D, Kremer A, Caragheorgheopol A, Sava M, Iordachescu C Pituitary. 2024; 27(2):178-186.

PMID: 38381238 DOI: 10.1007/s11102-024-01386-z.


Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.

Guarnotta V, Emanuele F, Salzillo R, Bonsangue M, Amato C, Mineo M Front Endocrinol (Lausanne). 2023; 14:1248985.

PMID: 37842314 PMC: 10569460. DOI: 10.3389/fendo.2023.1248985.


Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly.

Kuker A, Shen W, Jin Z, Chen J, Bruce J, Freda P J Endocr Soc. 2023; 7(5):bvad028.

PMID: 36922916 PMC: 10008673. DOI: 10.1210/jendso/bvad028.